Context Therapeutics Inc. (NASDAQ:CNTX) Stock Has Average Price Target of $6.17

Context Therapeutics Inc. (NASDAQ:CNTX) has earned a consensus rating of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $6.17.

A number of brokerages have issued reports on CNTX. Wall Street Zen downgraded Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Lifesci Capital cut Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Citigroup reiterated an “outperform” rating on shares of Context Therapeutics in a report on Thursday, August 6th. Maxim Group cut their target price on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Finally, Weiss Ratings downgraded shares of Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd.

Context Therapeutics Trading Down 9.8%

Shares of CNTX stock opened at $0.28 on Wednesday. The firm has a fifty day moving average price of $0.40 and a 200 day moving average price of $1.22. The company has a market cap of $25.27 million, a P/E ratio of -0.57 and a beta of 1.71. Context Therapeutics has a 12 month low of $0.27 and a 12 month high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Wednesday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.06). On average, equities analysts forecast that Context Therapeutics will post -0.45 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CNTX. Squarepoint Ops LLC acquired a new stake in shares of Context Therapeutics in the 2nd quarter valued at about $29,000. Bank of America Corp DE purchased a new position in Context Therapeutics during the 2nd quarter worth approximately $30,000. Two Sigma Securities LLC increased its position in Context Therapeutics by 388.7% during the second quarter. Two Sigma Securities LLC now owns 61,444 shares of the company’s stock worth $34,000 after buying an additional 48,871 shares during the period. Deutsche Bank AG acquired a new position in Context Therapeutics during the second quarter worth approximately $50,000. Finally, Clear Harbor Asset Management LLC acquired a new position in Context Therapeutics during the second quarter worth approximately $51,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

About Context Therapeutics

Context Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing targeted treatments for solid tumors, with an emphasis on therapies designed to address cancers with limited treatment options. The company is headquartered in Philadelphia, Pennsylvania, and its activities are centered on the discovery and clinical development of oncology medicines.

Context’s lead program is CTIM-76, an investigational bispecific T-cell engager designed to bind Claudin 6 (CLDN6) on tumor cells and CD3 on T cells.